{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:16:49Z","timestamp":1764951409262,"version":"3.46.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40119-025-00427-3","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T14:26:13Z","timestamp":1752935173000},"page":"601-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Healthcare Resource Utilization Among Patients with Hypertrophic Cardiomyopathy Hospitalized for Heart Failure in Japan"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-3186","authenticated-orcid":false,"given":"Yuika","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0960","authenticated-orcid":false,"given":"Bruno Casaes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-8469","authenticated-orcid":false,"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-9482","authenticated-orcid":false,"given":"Tsunehisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"427_CR1","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239\u2013311.","journal-title":"Circulation"},{"key":"427_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.24634","volume":"6","author":"L Alamo","year":"2017","unstructured":"Alamo L, Ware JS, Pinto A, et al. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. Elife. 2017;6:e24634.","journal-title":"Elife"},{"key":"427_CR3","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force Members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"427_CR4","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","volume":"85","author":"H Kitaoka","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, et al. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J. 2021;85:1590\u2013689.","journal-title":"Circ J"},{"key":"427_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:372\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"427_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjcard.2022.12.030","volume":"192","author":"NR Desai","year":"2023","unstructured":"Desai NR, Sutton MB, Xie J, et al. Clinical outcomes, resource utilization, and treatment over the disease course of symptomatic obstructive hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2023;192:16\u201323.","journal-title":"Am J Cardiol"},{"key":"427_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40119-024-00396-z","volume":"14","author":"Y Ikeda","year":"2025","unstructured":"Ikeda Y, Yamamoto T, Torigoe M, Casaes Teixeira B, Laurent T. Prevalence, patient characteristics, and treatment of patients with hypertrophic cardiomyopathy: a nationwide payer database study. Cardiol Ther. 2025;14:71\u201386.","journal-title":"Cardiol Ther"},{"key":"427_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","volume":"11","author":"AT Owens","year":"2022","unstructured":"Owens AT, Sutton MB, Gao W, et al. Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study. Cardiol Ther. 2022;11:249\u201367.","journal-title":"Cardiol Ther"},{"key":"427_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1253\/circrep.CR-20-0056","volume":"2","author":"T Kubo","year":"2020","unstructured":"Kubo T, Baba Y, Ochi Y, et al. Sudden cardiac death-related events of hypertrophic cardiomyopathy in a regional Japanese cohort\u2014results from Kochi RYOMA Study. Circ Rep. 2020;2:433\u20139.","journal-title":"Circ Rep"},{"key":"427_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (ShaRe). Circulation. 2018;138:1387\u201398.","journal-title":"Circulation"},{"key":"427_CR11","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","volume":"120","author":"EJ Rowin","year":"2017","unstructured":"Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol. 2017;120:2256\u201364.","journal-title":"Am J Cardiol"},{"key":"427_CR12","unstructured":"Mayo Clinic. Hypertrophic cardiomyopathy. https:\/\/www.mayoclinic.org\/diseases-conditions\/hypertrophic-cardiomyopathy\/symptoms-causes\/syc-20350198. Accessed 24 Feb 2025."},{"key":"427_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"427_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1253\/circj.CJ-22-0068","volume":"86","author":"Y Miyamoto","year":"2022","unstructured":"Miyamoto Y, Kubo T, Ochi Y, et al. Clinical features of heart failure in patients with hypertrophic cardiomyopathy in a regional Japanese cohort\u2014results from the Kochi RYOMA study. Circ J. 2022;86:1934\u201340.","journal-title":"Circ J"},{"key":"427_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40801-022-00315-5","volume":"9","author":"S Eguchi","year":"2022","unstructured":"Eguchi S, Morita Y, Mitani H, et al. Burden of repeated hospitalizations on patients with heart failure: an analysis of administrative and claims data in Japan. Drugs Real World Outcomes. 2022;9:377\u201389.","journal-title":"Drugs Real World Outcomes"},{"key":"427_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249711","volume":"16","author":"D Abe","year":"2021","unstructured":"Abe D, Inomata T. Actual state of \u201ctriple therapy\u201d for heart failure patients in eight regions of Japan: an analysis of a nationwide medical claims database. PLoS ONE. 2021;16:e0249711.","journal-title":"PLoS ONE"},{"key":"427_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40119-021-00212-y","volume":"10","author":"L Chen","year":"2021","unstructured":"Chen L, Ionescu-Ittu R, Romdhani H, et al. Disease management and outcomes in patients hospitalized for acute heart failure in Japan. Cardiol Ther. 2021;10:211\u201328.","journal-title":"Cardiol Ther"},{"key":"427_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/heartjnl-2023-322644","volume":"109","author":"HS Lumish","year":"2023","unstructured":"Lumish HS, Liang LW, Hasegawa K, et al. Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics. Heart. 2023;109:1837\u201343.","journal-title":"Heart"},{"key":"427_CR19","unstructured":"MDV EBM insight. MDV database overview. https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/. Accessed 22 Dec 2024."},{"key":"427_CR20","unstructured":"Ethical guidelines for medical research involving human subjects guidance. https:\/\/www.mhlw.go.jp\/content\/001087864.pdf. Accessed 22 Jan 2025."},{"key":"427_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031179","volume":"12","author":"R Nakamaru","year":"2023","unstructured":"Nakamaru R, Kohsaka S, Shiraishi Y, et al. Temporal trends in heart failure management and outcomes: insights from a Japanese multicenter registry of tertiary care centers. J Am Heart Assoc. 2023;12:e031179.","journal-title":"J Am Heart Assoc"},{"key":"427_CR22","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","volume":"31","author":"P Melacini","year":"2010","unstructured":"Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31:2111\u201323.","journal-title":"Eur Heart J"},{"key":"427_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","volume":"114","author":"KM Harris","year":"2006","unstructured":"Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216\u201325.","journal-title":"Circulation"},{"key":"427_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jacc.2005.04.062","volume":"46","author":"E Biagini","year":"2005","unstructured":"Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46:1543\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"427_CR25","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","volume":"65","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"427_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","volume":"102","author":"BJ Maron","year":"2000","unstructured":"Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858\u201364.","journal-title":"Circulation"},{"key":"427_CR27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29:1412\u201351.","journal-title":"J Card Fail"},{"key":"427_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00392-022-02076-1","volume":"112","author":"EM Screever","year":"2023","unstructured":"Screever EM, van der Wal MHL, van Veldhuisen DJ, et al. Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol. 2023;112:123\u201333.","journal-title":"Clin Res Cardiol"},{"key":"427_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.30","volume":"16","author":"VM van Deursen","year":"2014","unstructured":"van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103\u201311.","journal-title":"Eur J Heart Fail"},{"key":"427_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101491","volume":"54","author":"P Scicchitano","year":"2024","unstructured":"Scicchitano P, Massari F. The burden of congestion monitoring in acute decompensated heart failure: the need for multiparametric approach. Int J Cardiol Heart Vasc. 2024;54:101491.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"427_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CEOR.S405079","volume":"15","author":"C Izumi","year":"2023","unstructured":"Izumi C, Matsuyama R, Yamabe K, et al. In-hospital outcomes of heart failure patients with valvular heart disease: insights from real-world claims data. Clinicoecon Outcomes Res. 2023;15:349\u201360.","journal-title":"Clinicoecon Outcomes Res"},{"key":"427_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1253\/circj.CJ-18-1212","volume":"83","author":"K Kanaoka","year":"2019","unstructured":"Kanaoka K, Okayama S, Nakai M, et al. Hospitalization costs for patients with acute congestive heart failure in Japan. Circ J. 2019;83:1025\u201331.","journal-title":"Circ J"},{"key":"427_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013753","volume":"7","author":"N Sasaki","year":"2017","unstructured":"Sasaki N, Kunisawa S, Ikai H, Imanaka Y. Differences between determinants of in-hospital mortality and hospitalization costs for patients with acute heart failure: a nationwide observational study from Japan. BMJ Open. 2017;7: e013753.","journal-title":"BMJ Open"},{"key":"427_CR34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1253\/circj.70.1617","volume":"70","author":"H Tsutsui","year":"2006","unstructured":"Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, JCARE-CARD Investigators. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J. 2006;70:1617\u201323.","journal-title":"Circ J"},{"key":"427_CR35","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","volume":"73","author":"M Tsuchihashi-Makaya","year":"2009","unstructured":"Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893\u2013900.","journal-title":"Circ J"},{"key":"427_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2020.07.036","volume":"318","author":"M Ciabatti","year":"2020","unstructured":"Ciabatti M, Fumagalli C, Beltrami M, et al. Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2020;318:94\u2013100.","journal-title":"Int J Cardiol"},{"key":"427_CR37","doi-asserted-by":"publisher","first-page":"ehaa946.2085","DOI":"10.1093\/ehjci\/ehaa946.2085","volume":"41","author":"T Kubo","year":"2020","unstructured":"Kubo T, Takano H, Takayama M, et al. Baseline clinical features in a large-scale registration survey of patient with hypertrophic cardiomyopathy throughout Japan: J-HCM registry study. Eur Heart J. 2020;41:ehaa946.2085.","journal-title":"Eur Heart J"},{"key":"427_CR38","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jchf.2024.12.006","volume":"13","author":"M Amano","year":"2025","unstructured":"Amano M, Kitaoka H, Yoshikawa Y, REVEAL-HCM Investigators, et al. Validation of guideline recommendation on sudden cardiac death prevention in hypertrophic cardiomyopathy. JACC Heart Fail. 2025;13:1014\u201326.","journal-title":"JACC Heart Fail."},{"key":"427_CR39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/heartjnl-2023-323856","volume":"110","author":"K Akita","year":"2024","unstructured":"Akita K, Kageyama S, Suzuki S, et al. Searching for atrial fibrillation and early recruitment of Heart Failure in HCM (SAFER-HCM) Registry Investigators. Machine learning-based detection of sleep-disordered breathing in hypertrophic cardiomyopathy. Heart. 2024;110:954\u201362.","journal-title":"Heart"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00427-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:14:38Z","timestamp":1764951278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00427-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00427-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"type":"print","value":"2193-8261"},{"type":"electronic","value":"2193-6544"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuika Ikeda, Bruno Casaes Teixeira, Thomas Laurent, and Tsunehisa Yamamoto are employees of Bristol Myers Squibb, and own stocks in Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study used de-identified claims\/EMR data and, therefore, did not require ethics committee review. In addition, this study did not require informed consent to be obtained from patients. This study was conducted in accordance with the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices and applicable regulatory requirements [\n                      \n                      ]. This article is based on information from an existing database and does not contain any new studies with human participants or animals performed by any of the authors [\n                      \n                      ]. Since the database is available in the public domain (\n                      \n                      ), no permission was obtained to access and use the data from the database utilized in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}